Pivotal Point Tracking Absci (ABSI): Generative AI in Drug Development - Study Success and 100 Million USD Funding

Absci is a biotech company that utilizes generative AI to drastically accelerate the development of new antibody therapies. On June 24, the stock experienced a massive surge. The trigger was positive interim results from the Phase 1 clinical trial HEADLINE for the drug candidate ABS-201, intended for the treatment of hair loss (androgenetic alopecia). No severe side effects were reported. At the same time, Absci arranged for a stock placement of 100 million USD, which was participated in by the pharmaceutical giant Eli Lilly and other renowned institutional...